Erratum to: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

Abstract

The authors were listed in the wrong order, and one of their names was spelt incorrectly. These mistakes are rectified here.The online version of the original article can be found htt://dx

Lutetium 177-DOTA-TATE therapy for esthesioneuroblastoma: A case report

“…Lutetium-177 ( 177 Lu) is a radionuclide that emits β particles and γ photons, and can be used in the treatment of certain neoplasms when attached to a somatostatin analogue, such as DOTA-octreotate (known as 177 Lu-DOTA-TATE). Patients with somatostatin-positive neuroendocrine tumors may be administered three to four doses of 177 Lu-DOTA-TATE intravenously, accumulating a total dose of 22,200-29,600 GBq (18,19). Co-treatment with amino acids (such as 2.5% arginine and 2.5% lysine) is recommended for renal protection, and is administered prior to and following each therapeutic dose (20).…”

Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths

“…Alternatively, new agents have been proposed including the alpha particle emitting radionuclide 213 Bi [47]. Overall, however, there exists no general consensus on the treatment protocol, as is evident in the ambiguity of the consensus guidelines on PRRT by the European Neuroendocrine Tumor Society (ENETS) or from the International Atomic Energy Agency (IAEA) [23].…”

“…If pretreatment assessment establishes the presence of adequate SST receptors on tumors, either by use of SST receptor scintigraphy or 68 Ga SST receptor positron emission tomography (PET)/CT, treatment can be considered feasible [23]. Under such circumstances, radionuclide-labeled SST analogs, e.g., 177 Lu-DOTATATE, can be used to deliver cytotoxic radiation doses to the tumor with consistent cumulative absorbed doses, reaching, in several cases, values up to 250-300 Gy.…”

Nowotwory neuroendokrynne żołądka i dwunastnicy z uwzględnieniem gastrinoma (zasady postępowania rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)

“…Isotope therapy with labelled somatostatin analogues (Peptide Receptor Radionuclide Therapy -PRRT) is a form of palliative treatment rarely used in gastric NENs [46,76,77]. Eligibility for the treatment is in accordance with the principles presented in the general section.…”

“…In advanced gastroduodenal NET G3, PRRT may be considered when other treatment methods have been exhausted, and a high somatostatin receptor expression is maintained in the SRI examination. The literature data on this subject are limited to individual cases [46,77,79,[80][81].…”